녹내장 시장 규모, 점유율 및 성장 분석 : 유형별, 약제 클래스별, 투여 경로별, 최종 용도별, 유통경로별, 지역별 - 업계 예측(2026-2033년)

Glaucoma Market size was valued at USD 8.7 Billion in 2024 and is poised to grow from USD 9.19 Billion in 2025 to USD 14.21 Billion by 2033, growing at a CAGR of 5.6% during the forecast period (2026-2033).

The global glaucoma market is experiencing notable growth fueled by an increase in the prevalence of this chronic eye condition, which can result in irreversible vision loss if untreated. The aging population and the rising occurrence of chronic eye ailments further contribute to market expansion. Innovations in diagnostics and treatment, including minimally invasive surgical techniques and advanced laser therapies, are enhancing market dynamics. Nonetheless, challenges such as high treatment costs and inadequate healthcare access in certain areas present obstacles to growth. The landscape is marked by intense competition among leading players, prompting continuous research and development to produce cutting-edge glaucoma management solutions. Overall, heightened awareness and improved diagnostic and therapeutic options are anticipated to sustain market momentum.

Top-down and bottom-up approaches were used to estimate and validate the size of the Glaucoma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Glaucoma Market Segments Analysis

Global Glaucoma Market is segmented by type, drug class, administration, end use, distribution and region. Based on type, the market is segmented into closed angle glaucoma (CAG), open angle glaucoma (OAG), secondary glaucoma, congenital glaucoma and others. Based on drug class, the market is segmented into beta blockers, prostaglandins, alpha adrenergic agonist, carbonic anhydrase inhibitors, combination drugs and others. Based on administration, the market is segmented into oral, injections, intravitreal and other. Based on end use, the market is segmented into hospitals, specialty centers and others. Based on distribution, the market is segmented into hospital, online and retail. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Glaucoma Market

A significant factor propelling the glaucoma market is the rising global prevalence of this ocular condition. The aging demographic, alongside the increase in chronic health issues such as diabetes and hypertension, has led to a higher incidence of glaucoma cases. Given that glaucoma is a primary cause of irreversible blindness, the urgency for timely detection, accurate diagnosis, and effective treatment has intensified. This heightened awareness and necessity spur the demand for cutting-edge glaucoma management options, encompassing sophisticated diagnostic equipment, effective pharmacological therapies, and advanced surgical techniques to address this critical health concern.

Restraints in the Glaucoma Market

A significant challenge facing the glaucoma market is the widespread lack of awareness and inadequate routine screening practices for this condition in numerous areas. Since glaucoma frequently remains asymptomatic during its early phases, effective diagnosis relies heavily on consistent eye examinations. This knowledge gap among both the public and healthcare providers can lead to delays in diagnosis and intervention, which may ultimately result in preventable vision impairment. Furthermore, the substantial financial burden associated with managing glaucoma-encompassing the costs of medications, surgical procedures, and ongoing follow-up care-represents a critical barrier to accessibility, particularly for individuals in low- and middle-income regions.

Market Trends of the Glaucoma Market

The global glaucoma market is witnessing a significant trend towards the adoption of cutting-edge diagnostic technologies and innovative treatment solutions. As awareness of glaucoma's potential to cause irreversible vision loss rises, there is an intensified focus on early detection and management strategies. This trend is characterized by the integration of advanced imaging and diagnostic tools, including optical coherence tomography (OCT), visual field assessments, and sophisticated tonometry techniques. These technologies enhance the accuracy of glaucoma diagnosis and ongoing monitoring, enabling healthcare providers to implement timely interventions. Consequently, this market shift is expected to improve patient outcomes and elevate the standard of care in glaucoma management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Glaucoma Market Size by Type & CAGR (2026-2033)

• Market Overview
• Closed Angle Glaucoma (CAG)
• Open Angle Glaucoma (OAG)
• Secondary Glaucoma
• Congenital Glaucoma
• Others

Global Glaucoma Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Beta Blockers
• Prostaglandins
• Alpha Adrenergic Agonist
• Carbonic Anhydrase Inhibitors
• Combination Drugs
• Others

Global Glaucoma Market Size by Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injections
• Intravitreal
• Other

Global Glaucoma Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Centers
• Others

Global Glaucoma Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital
• Online
• Retail

Global Glaucoma Market Size & CAGR (2026-2033)

• North America (Type, Drug Class, Administration, End Use, Distribution)
  • US
  • Canada
• Europe (Type, Drug Class, Administration, End Use, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Administration, End Use, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Administration, End Use, Distribution)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Administration, End Use, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Aerie Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akorn, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inotek Pharmaceuticals Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glaukos Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocular Therapeutix, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ono Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nicox S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Visiox Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TearClear (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MediPrint Ophthalmics (formerly Leo Lens Pharma) (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tarsier Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Peregrine Ophthalmic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations